European Patent Granted for ECG-Based Assessment of Diastolic Function, Expands HeartSciences' Patent Portfolio to More Than 45 Granted Patents

Southlake, TX — HeartSciences Inc. (Nasdaq: HSCS / HSCSW), a healthcare information technology (HIT) company focused on advancing electrocardiography (ECG/EKG) through the integration of artificial intelligence (AI), today announced the grant by the European Patent Office (EPO) of European Patent No. EP4252651, titled "Electrocardiogram-Based Assessment of Diastolic Function." The patent covers machine-learning models and methods for computing quantitative estimates of echocardiogram parameters indicative of diastolic function using ECG data and patient demographic parameters.

"Securing European patent protection for ECG-based assessment of diastolic function is an important expansion of our AI-ECG intellectual property portfolio," said Andrew Simpson, CEO of HeartSciences. "Diastolic dysfunction is an important indicator of cardiac disease that has traditionally required imaging-based assessment. This grant further reinforces our strategy of transforming the ECG into a far more valuable front-line cardiac screening tool and underlines the considerable embedded IP value in HeartSciences. We believe the breadth of our patent portfolio provides a meaningful commercial advantage as the field of AI-ECG continues to expand."

The patented technology uses machine learning models, trained on ECG and echocardiography data, to estimate echocardiogram parameters indicative of diastolic function directly from a patient's ECG.

The patent took effect as a Unitary Patent on April 29, 2026, and provides coverage in 19 European countries: Austria, Belgium, Bulgaria, Croatia, Denmark, Estonia, Finland, France, Germany, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Portugal, Romania, Slovenia and Sweden. With this grant, HeartSciences' intellectual property portfolio now includes more than 45 granted patents.